Search hospitals

>

Colorado

>

Denver

National Jewish Health

Claim this profile

Denver, Colorado 80206

Global Leader in Cystic Fibrosis

Global Leader in Asthma

Conducts research for Idiopathic Pulmonary Fibrosis

Conducts research for Chronic Obstructive Pulmonary Disease

Conducts research for Lung Cancer

474 reported clinical trials

26 medical researchers

Photo of National Jewish Health in DenverPhoto of National Jewish Health in DenverPhoto of National Jewish Health in Denver

Summary

National Jewish Health is a medical facility located in Denver, Colorado. This center is recognized for care of Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease, Lung Cancer and other specialties. National Jewish Health is involved with conducting 474 clinical trials across 487 conditions. There are 26 research doctors associated with this hospital, such as Nicholas DiBella, Benjamin J. George, Marwan Massouh, and Karng S. Log.

Area of expertise

1

Cystic Fibrosis

Global Leader

National Jewish Health has run 89 trials for Cystic Fibrosis. Some of their research focus areas include:

CFTR
CFTR positive
sweat chloride
2

Asthma

Global Leader

National Jewish Health has run 74 trials for Asthma.

Top PIs

Clinical Trials running at National Jewish Health

Cystic Fibrosis

Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis

Pulmonary Hypertension

Lung Cancer

Food Allergy

Asthma

Esophageal cancer

Breast Cancer

Insomnia

Image of trial facility.

Sinus Surgery

for Cystic Fibrosis

This study will be a prospective, observational study of patients who undergo endoscopic sinus surgery for cystic fibrosis-related chronic rhinosinusitis (CRS). Individuals who do not undergo surgery but are treated medically for CRS will also be enrolled to serve as a control group. Outcomes analyzed will include pulmonary, quality of life, and others.

Recruiting

1 award

N/A

5 criteria

Image of trial facility.

Triple Therapy Modulator

for Cystic Fibrosis

RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.

Recruiting

1 award

N/A

10 criteria

Image of trial facility.

Remote Sputum Collection

for Cystic Fibrosis

Elexacaftor/Tezacaftor/Ivacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production. Diagnosing lung infections has become more challenging due to the decrease in sputum and rise of telehealth services. While the option of collecting sputum samples at home and sending them by mail may be feasible, uncertainty remains about how the collection of samples outside of clinic and delays in testing while in the mail impact infection detection. This study will compare bacterial cultures using sputum samples collected at home versus samples collected in clinic (saline-induced sputum and throat swab). This study seeks to shed light on how valuable home collected samples can be and help us better understand the usefulness of home-collected sputum samples for both clinical and research purposes.

Recruiting

1 award

N/A

3 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at National Jewish Health?

Where is National Jewish Health located?

Who should I call to ask about financial aid or insurance network?

What insurance does National Jewish Health accept?

What awards or recognition has National Jewish Health received?